Results 41 to 50 of about 1,632,256 (263)

Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen

Nature Communications
T cell receptor-engineered T cells (TCR-T) could be advantageous in glioblastoma by allowing safe and ubiquitous targeting of the glioblastoma-derived peptidome.
Yu-Chan Chih, Amelie C. Dietsch, Philipp Koopmann, Xiujian Ma, Dennis A. Agardy, Binghao Zhao, Alice De Roia, Alexandros Kourtesakis, Michael Kilian, Christopher Krämer, Abigail K. Suwala, Miriam Stenzinger, Halvard Boenig, Agnieszka Blum, Victor Murcia Pienkowski, Kuralay Aman, Jonas P. Becker, Henrike Feldmann, Theresa Bunse, Richard Harbottle, Angelika B. Riemer, Hai-Kun Liu, Nima Etminan, Felix Sahm, Miriam Ratliff, Wolfgang Wick, Michael Platten, Edward W. Green, Lukas Bunse   +28 more
doaj   +1 more source

T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome

Haematologica, 2009
Background A T-cell clone, thought to be the source of eosinophilopoietic cytokines, identified by clonal rearrangement of the T-cell receptor and by the presence of aberrant T-cell immunophenotype in peripheral blood defines lymphocytic variant of ...
Grzegorz Helbig, Agata Wieczorkiewicz, Joanna Dziaczkowska-Suszek, Miroslaw Majewski, Slawomira Kyrcz-Krzemien   +4 more
doaj   +1 more source

A Systematic Review of Evidence on the Clinical Effectiveness of Surveillance Imaging in Children With Medulloblastoma and Ependymoma

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Surveillance imaging aims to detect tumour relapse before symptoms develop, but it's unclear whether earlier detection of relapse leads to better outcomes in children and young people (CYP) with medulloblastoma and ependymoma. This systematic review aims to identify relevant literature to determine the efficacy of surveillance magnetic ...
Lucy Shepherd, Melissa Taylor, Helen Fulbright, Bob Phillips   +3 more
wiley   +1 more source

Chimeric Antigen Receptor-T Cell Therapy

HemaSphere, 2018
. Chimeric antigen receptor (CAR)-T cell therapy is a new class of cellular immunotherapies that involves ex vivo genetic modification of T cells to incorporate an engineered CAR.
Jochen Buechner, Marie José Kersten, Miriam Fuchs, Florence Salmon, Ulrich Jäger   +4 more
doaj   +1 more source

Prognostic Impact of Treatment Modalities, Including Targeted Compartmental Radio‐Immunotherapy, in a Cohort of Neuroblastoma Patients With CNS Metastases at Relapse

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction Neuroblastoma (NB) with central nervous system (CNS) metastases is rare at diagnosis, but occurs more often during relapse/progression. Patients with CNS metastases face a dismal prognosis, with no standardized curative treatment available.
Vicente Santa‐Maria Lopez, Anna Felip‐Badia, Marina Caballero‐Bellon, Nazaret Sanchez‐Sierra, Alicia Castañeda, Moira Garraus, Maite Gorostegui, Margarida Simão‐Rafael, Juan Pablo Muñoz, Marta Perez‐Somarriba, Salvador Mañe, Mariana Cecilia Planells, Sara Perez‐Jaume, Jaume Mora   +13 more
wiley   +1 more source

Glutamate receptor–T cell receptor signaling potentiates full CD8+ T cell activation and effector function in tumor immunity

iScience
Summary: Glutamate is best known as an excitatory neurotransmitter. However, its roles in T cell immunity remain underrecognized. We investigated the interplay between glutamate receptors (GluRs) and T cell receptors (TCRs) during CD8+ T cell activation.
Maria Teresa P. de Aquino, Thomas W. Hodo, Salvador González Ochoa, Roman V. Uzhachenko, Muna A. Mohammed, J. Shawn Goodwin, Thanigaivelan Kanagasabai, Alla V. Ivanova, Anil Shanker   +8 more
doaj   +1 more source

Improved Outcomes for Older Children, Adolescents, and Young Adults With Neuroblastoma in the Post‐Immunotherapy Era: An Updated Report From the International Neuroblastoma Risk Group

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background We describe clinical and biologic characteristics of neuroblastoma in older children, adolescents, and young adults (OCAYA); describe survival outcomes in the post‐immunotherapy era; and identify if there is an age cut‐off that best discriminates outcomes.
Rebecca J. Deyell, Kavitha Srivatsa, Paola Angelini, Pei‐Chi Kao, Brady Payne, Arlene Naranjo, Sveva Castelli, Miho Kato, Miki Ohira, Ulriche Pöetschger, Yaël Mossé, Lucas Moreno, Meredith S. Irwin, Ramya Ramanujachar, Wendy B. London   +14 more
wiley   +1 more source

Novel chimeric antigen receptor T cells based on T-cell receptor-like antibodies

Blood Science, 2019
. The need for novel therapeutics against human cancers such as leukemias and solid tumors is well recognized. Human T cells are poised to make a fundamental change in the therapeutic approach. T-cell interaction with a tumor cell is a critical event and
Qi Zhao
doaj   +1 more source

Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers [PDF]

, 2023
Scott A. Becker, Brian G. Petrich, Bing Yu, Kristopher A. Knight, Harrison C. Brown, Sunil S. Raikar, Christopher B. Doering, H. Trent Spencer   +7 more
openalex   +1 more source

T cell receptor-engineered T cells for leukemia immunotherapy

Cancer Cell International, 2019
At present, refractory and relapse are major issues for leukemia therapy and a major cause of allogeneic hematopoietic stem cell transplant failure. Over the last decade, many studies have demonstrated that adoptive cancer antigen-specific T cell therapy
Yikai Zhang, Yangqiu Li
doaj   +1 more source